SUBSCRIBE
SUBSCRIBE
News   Drug Development

ReNeuron Says Initial Tests On Stroke Treatment OK

November 18, 2005 | 
1 min read
Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
Preclinical Europe
MORE ON THIS TOPIC
FDA headquarters with a purple psychedelic background.
Psychedelics
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed
July 14, 2026
 · 
3 min read
 · 
Michael Gibney
Open Door in the room, interior background. Symbol of new way, exit, discovery, new opportunities. Business motivation concept, vector illustration
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
July 13, 2026
 · 
4 min read
 · 
Heather McKenzie
Insights
From sequence to scale: Gene editing’s new era in biologics manufacturing
July 10, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
July 10, 2026
 · 
1 min read
 · 
Gabrielle Masson